Literature DB >> 28583576

Administration of Huperzine A exerts antidepressant-like activity in a rat model of post-stroke depression.

Yuan Du1, Haiyue Liang2, Leiming Zhang3, Fenghua Fu4.   

Abstract

Post-stroke depression (PSD) is the most common mood disorder following a stroke, and is also the main factor limiting recovery and rehabilitation in stroke patients. The present study was aimed to investigate whether Huperzine A (HupA) has antidepressant-like activity in a rat model of PSD, which was developed by middle cerebral artery occlusion followed by an 18-day chronic unpredictable mild stress in conjunction with isolation rearing. The sucrose preference and forced swim tests were used to assess depression-like behavior. Neurological and cognitive functions following ischemia were evaluated by neurological evaluation, the beam-walking test, the forelimb grip force test, and the water maze test. Levels of norepinephrine (NE), dopamine (DA), and 5-hydroxytryptamine (5-HT) in the hippocampus and prefrontal cortex were assayed by high performance liquid chromatography. Western blot analysis was used to evaluate hippocampal expression of the 5-hydroxytryptamine 1A receptor (5-HT1AR), cAMP response element binding (CREB), phosphorylated CREB (p-CREB) and brain-derived neurotrophic factor (BDNF). The results showed that treatment with HupA for 4weeks ameliorated behavioral abnormalities and the impairment of neurological and cognitive functions in PSD rats. This was accompanied by the upregulated hippocampal expression of 5-HT1AR, p-CREB and BDNF, and increased levels of NE, DA, and 5-HT in the hippocampus and prefrontal cortex. These findings suggest that HupA has antidepressant-like effect and can improve neurological and cognitive functions in PSD rats, which suggest its therapeutic potential for depression after stroke.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognitive function; Huperzine A; Neurological function; Neurotransmitter; Post-stroke depression

Mesh:

Substances:

Year:  2017        PMID: 28583576     DOI: 10.1016/j.pbb.2017.06.002

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

Review 1.  A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis.

Authors:  Mayuri Shukla; Prapimpun Wongchitrat; Piyarat Govitrapong
Journal:  Neurochem Res       Date:  2022-02-05       Impact factor: 3.996

Review 2.  Traditional Chinese Medicine in Depression Treatment: From Molecules to Systems.

Authors:  Chan Li; Junying Huang; Yung-Chi Cheng; Yuan-Wei Zhang
Journal:  Front Pharmacol       Date:  2020-05-07       Impact factor: 5.810

Review 3.  Repurposing Cholinesterase Inhibitors as Antidepressants? Dose and Stress-Sensitivity May Be Critical to Opening Possibilities.

Authors:  Paul J Fitzgerald; Pho J Hale; Anjesh Ghimire; Brendon O Watson
Journal:  Front Behav Neurosci       Date:  2021-01-14       Impact factor: 3.558

Review 4.  Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer's Disease.

Authors:  María Jesús Friedli; Nibaldo C Inestrosa
Journal:  Molecules       Date:  2021-10-29       Impact factor: 4.411

Review 5.  The Relationship Between 5-Hydroxytryptamine and Its Metabolite Changes With Post-stroke Depression.

Authors:  Simeng Gu; Zhengming He; Qiuyue Xu; Jie Dong; Tingwei Xiao; Fei Liang; Xianjun Ma; Fushun Wang; Jason H Huang
Journal:  Front Psychiatry       Date:  2022-04-26       Impact factor: 5.435

6.  CysLT2R Antagonist HAMI 3379 Ameliorates Post-Stroke Depression through NLRP3 Inflammasome/Pyroptosis Pathway in Gerbils.

Authors:  Li Zhou; Jiajia Zhang; Xue Han; Jie Fang; Shasang Zhou; Lingqun Lu; Qiaojuan Shi; Huazhong Ying
Journal:  Brain Sci       Date:  2022-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.